Clinical Trial: Pasireotide Treatment for Neuroendocrine Tumor

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional

Official Title: Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor

Brief Summary: Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.

Detailed Summary:
Sponsor: University of Maryland

Current Primary Outcome: Hypoglycemia [ Time Frame: up to 12 months ]

number of times glucose < 70 mg/dl with and without symptoms


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Maryland

Dates:
Date Received: May 16, 2016
Date Started: April 2016
Date Completion:
Last Updated: June 6, 2016
Last Verified: June 2016